(MedPage Today) -- No women taking long-acting cabotegravir (Apretude) for HIV pre-exposure prophylaxis (PrEP) developed an HIV infection despite short delays before some maintenance injections, according to a U.S. study of routine clinical care...
Cabotegravir HIV PrEP Effective Among U.S. Women Despite Treatment Interruptions
